AbbVie and Galapagos go after cystic fibrosis; FDA's NME approval pace slows; government shutdown could slow ad-com votes; and a report shows privately insured patients had emptier pockets in 2012 than 2011
With sequester cuts taking effect and no sign of a deal to end them in sight, FDA stands to lose 5% of its 2013 budget—though coming five months into the Federal fiscal year, it will feel more like 9%—and while the agency has said it has no plans at present for layoffs, it's certain the approvals process will slow as the agency absorbs the loss.
The advent of new ad-unit lengths is bringing drugmakers much-needed relief from the high cost of advertising on television.
An analysis of a cross-section of the pharma industry shows budgets of pharmaceutical marketing research teams are starting to recover from 2008 lows.
Total global pharma promotional spending fell 3.4% to $92.2 billion in 2011, according to Cegedim Strategic Data, led by a 4.7% decline in detailing spend.
President Obama's proposed 2013 budget would mandate an estimated $156 billion in new rebates to low-income seniors through Medicare over the next decade - discounts that would come out of the pockets of drug companies and could cost tens of thousands of jobs, according to PhRMA.
Pharma spending on consumer advertising was largely flat in 2009, rising 1.9% to $4.5 billion over 2008 spend, according to data from The Nielsen Company. That's good news for media companies, suggesting that spending has hit bottom following two years of steep declines.
In an age of accountability, where every dollar counts, Deborah Dick-Rath talks to industry insiders about how they can make a measurable difference in their marketing mix